Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 48

Related Articles by Review for PubMed (Select 14664727)

1.

Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review.

Brewer GJ, Merajver SD.

Integr Cancer Ther. 2002 Dec;1(4):327-37. Review.

PMID:
14664727
2.

Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease.

Brewer GJ.

Exp Biol Med (Maywood). 2001 Jul;226(7):665-73. Review.

PMID:
11444102
3.

Control of copper status for cancer therapy.

Goodman VL, Brewer GJ, Merajver SD.

Curr Cancer Drug Targets. 2005 Nov;5(7):543-9. Review.

PMID:
16305350
4.

Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation.

Brewer GJ.

J Cell Mol Med. 2003 Jan-Mar;7(1):11-20. Review. Erratum in: J Cell Mol Med. 2003 Apr-Jun;7(2):1 p proceeding table of contents.

PMID:
12767257
5.

Copper lowering therapy with tetrathiomolybdate as an antiangiogenic strategy in cancer.

Brewer GJ.

Curr Cancer Drug Targets. 2005 May;5(3):195-202. Review.

PMID:
15892619
6.

Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm.

Khan G, Merajver S.

Expert Opin Investig Drugs. 2009 Apr;18(4):541-8. doi: 10.1517/13543780902845622 . Review.

PMID:
19335282
7.
8.

Copper deficiency as an anti-cancer strategy.

Goodman VL, Brewer GJ, Merajver SD.

Endocr Relat Cancer. 2004 Jun;11(2):255-63. Review.

9.

Anticopper therapy against cancer and diseases of inflammation and fibrosis.

Brewer GJ.

Drug Discov Today. 2005 Aug 15;10(16):1103-9. Review.

PMID:
16182195
10.

The use of copper-lowering therapy with tetrathiomolybdate in medicine.

Brewer GJ.

Expert Opin Investig Drugs. 2009 Jan;18(1):89-97. doi: 10.1517/13543780802621859 . Review.

PMID:
19053885
11.

Antiangiogenic therapy through copper chelation.

Sproull M, Brechbiel M, Camphausen K.

Expert Opin Ther Targets. 2003 Jun;7(3):405-9. Review.

PMID:
12783576
12.

Copper chelation as an antiangiogenic therapy.

Lowndes SA, Harris AL.

Oncol Res. 2004;14(11-12):529-39. Review.

PMID:
15666995
13.

The risks of free copper in the body and the development of useful anticopper drugs.

Brewer GJ.

Curr Opin Clin Nutr Metab Care. 2008 Nov;11(6):727-32. doi: 10.1097/MCO.0b013e328314b678. Review.

PMID:
18827576
15.

Novel therapeutic approaches to the treatment of Wilson's disease.

Brewer GJ.

Expert Opin Pharmacother. 2006 Feb;7(3):317-24. Review.

PMID:
16448326
16.
17.

Role of copper in tumour angiogenesis--clinical implications.

Nasulewicz A, Mazur A, Opolski A.

J Trace Elem Med Biol. 2004;18(1):1-8. Review.

PMID:
15487757
18.

Zinc acetate for the treatment of Wilson's disease.

Brewer GJ.

Expert Opin Pharmacother. 2001 Sep;2(9):1473-7. Review.

PMID:
11585025
19.

Copper imbalances in ruminants and humans: unexpected common ground.

Suttle NF.

Adv Nutr. 2012 Sep 1;3(5):666-74. doi: 10.3945/an.112.002220. Review.

20.

Chelators at the cancer coalface: desferrioxamine to Triapine and beyond.

Yu Y, Wong J, Lovejoy DB, Kalinowski DS, Richardson DR.

Clin Cancer Res. 2006 Dec 1;12(23):6876-83. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk